Analysts Issue Forecasts for Curis FY2025 Earnings

Curis, Inc. (NASDAQ:CRIS) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Curis in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the biotechnology company will post earnings per share of ($2.34) for the year. The consensus estimate for Curis’ current full-year earnings is ($7.12) per share.

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Curis in a research note on Tuesday, December 10th.

Curis Price Performance

Shares of Curis stock opened at $3.27 on Thursday. Curis has a 52 week low of $2.86 and a 52 week high of $17.49. The business has a 50 day moving average price of $3.65 and a 200-day moving average price of $4.75.

Institutional Trading of Curis

An institutional investor recently raised its position in Curis stock. Point72 Asset Management L.P. grew its position in shares of Curis, Inc. (NASDAQ:CRIS) by 795.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 108,356 shares of the biotechnology company’s stock after acquiring an additional 96,256 shares during the period. Point72 Asset Management L.P. owned about 1.84% of Curis worth $748,000 as of its most recent SEC filing. Institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.